Risk factor
Good trading liquidity
Profitability factor
Very strong margins and returns
About
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of UTHR is 616 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell